# WNT5A Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- WNT5A is a secreted morphogen crucial for embryonic development, acting as a primary activator of non-canonical Wnt signaling pathways (Planar Cell Polarity and Wnt/Ca²⁺) while antagonizing canonical β-catenin signaling. Its structure is characterized by a conserved WNT fold stabilized by disulfide bonds, with critical post-translational modifications including palmitoleoylation at Ser209 essential for secretion and receptor binding.
- The *WNT5A* gene locus on chromosome 3p14.3 is regulated by complex promoter and enhancer elements responsive to transcription factors like TCF/LEF, NF-κB, p53, and ERα, as well as developmental cues (HOXD13, MSX1, SOX2/SOX9) and immune stimuli (PU.1, C/EBPβ). Aberrant expression is linked to diseases such as Robinow syndrome, various cancers, osteoarthritis, and pulmonary fibrosis.
- Pathogenic germline mutations in *WNT5A*, particularly missense variants clustering in the lipid-binding pocket or ROR2-binding interface, cause autosomal dominant Robinow syndrome, characterized by skeletal dysplasia and distinctive facial features. Somatic mutations and copy number alterations are observed in cancers like melanoma and gastric cancer, often correlating with increased invasiveness.
- WNT5A signaling is hijacked by viruses (HBV, HTLV-1, EBV) and bacteria (H. pylori, Salmonella) to promote viral replication, host cell transformation, or immune evasion. In cancer, WNT5A can promote metastasis and create an immunosuppressive tumor microenvironment by influencing cell migration and antigen presentation.
- Therapeutic strategies targeting WNT5A include Porcupine (PORCN) inhibitors (e.g., LGK974, ETC-159) that block WNT ligand lipidation, WNT5A mimetic peptides (agonists like Foxy5, antagonists like Box5), and RNA-based approaches like antisense oligonucleotides (ASOs) and siRNA nanoparticles to reduce WNT5A expression. Resistance to therapies like BRAF inhibitors and tamoxifen can be mediated by WNT5A pathway alterations.

---

## Executive Summary & Key Metadata

WNT5A (Wingless-Type MMTV Integration Site Family, Member 5A) encodes a secreted lipid-modified glycoprotein that functions as a morphogen and signaling ligand. It is a prototypical activator of the non-canonical Wnt signaling cascades, including the planar cell polarity (PCP) pathway and the Wnt/Ca²⁺ pathway, while simultaneously acting as a context-dependent antagonist of canonical β-catenin-dependent transcription. The gene product is fundamental to embryonic axis specification, chondrogenesis, neuronal guidance, and immune cell polarization. Dysregulation of WNT5A expression or signaling is a hallmark of multiple malignancies, inflammatory disorders, and congenital skeletal dysplasias such as Robinow syndrome.

| **Attribute** | **Detail** |
|---|---|
| HGNC Symbol | WNT5A |
| UniProt Accession | P41221 |
| Representative PDB ID | True (e.g., 4F0A for human WNT5A) |
| Chromosomal Locus | 3p14.3 (GRCh38: chr3:55,465,715-55,490,539) |
| Primary Molecular Function | Secreted signaling ligand; non-canonical Wnt pathway activator; β-catenin antagonist |
| Disease & Pathology Associations | Robinow syndrome (autosomal dominant), breast cancer, melanoma, gastric cancer, osteoarthritis, schizophrenia, pulmonary fibrosis |
| Expression Pattern | High in fetal brain, limb buds, neural crest; low in adult tissues; re-expressed in tumors |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Coordinates and Gene Structure

The human *WNT5A* gene is located on the short arm of chromosome 3 at band p14.3. The reference genome (GRCh38/hg38) places the gene between positions 55,465,715 and 55,490,539 on the forward strand. The gene spans approximately 24.8 kilobases of genomic DNA. The locus is flanked by the *SLC25A26* gene (encoding a mitochondrial S-adenosylmethionine carrier) on the centromeric side and *WNT5A-AS1* (a long non-coding antisense RNA) on the telomeric side. The antisense transcript is transcribed from the opposite strand and has been implicated in post-transcriptional regulation of WNT5A mRNA stability.

The gene comprises five exons and four introns. Exon 1 is entirely untranslated (5' UTR) and contains the core promoter elements. Exon 2 contains the translation initiation codon and encodes the N-terminal signal peptide. Exons 3 and 4 encode the majority of the mature protein, including the conserved WNT homology domains. Exon 5 contains the 3' UTR, which harbors multiple AU-rich elements (AREs) and binding sites for microRNAs such as miR-374a and miR-29a.

### 1.2 Promoter Architecture and Transcriptional Regulation

The proximal promoter of *WNT5A* lacks a canonical TATA box but contains a high GC content and multiple Sp1 binding sites. The core promoter spans approximately 1.2 kb upstream of the transcription start site (TSS). Functional cis-regulatory elements identified through chromatin immunoprecipitation (ChIP-seq) and reporter assays include:

- **T-cell factor/lymphoid enhancer factor (TCF/LEF) binding sites**: These are paradoxical because WNT5A is often a β-catenin antagonist, yet its promoter contains functional TCF/LEF motifs. This suggests a negative feedback loop where canonical Wnt signaling can induce WNT5A expression, which then acts to suppress the same pathway.
- **NF-κB response elements**: Located at positions -850 to -840 and -320 to -310 relative to the TSS. These elements mediate WNT5A induction by inflammatory cytokines such as TNF-α and IL-1β.
- **p53 response elements**: Two consensus p53 half-sites exist in the distal promoter. DNA damage induces p53 binding and subsequent WNT5A transcription, linking genotoxic stress to non-canonical Wnt signaling.
- **Estrogen response elements (EREs)**: A half-ERE at -540 to -530 allows for estrogen receptor α (ERα)-dependent transcription in hormone-responsive tissues.

### 1.3 Enhancer Elements and Chromatin Architecture

Three enhancer regions have been validated via Hi-C and enhancer RNA (eRNA) profiling:

1. **Enhancer E1** (chr3:55,470,000-55,471,500): Active in limb bud mesenchyme. Contains binding motifs for HOXD13 and MSX1, transcription factors critical for limb development. Deletion of E1 in mice recapitulates the distal limb malformations seen in WNT5A knockout animals.
2. **Enhancer E2** (chr3:55,480,200-55,481,800): Active in the dorsal neural tube. Contains a SOX2/SOX9 composite binding site. This enhancer is methylated in adult tissues, contributing to the silencing of WNT5A in differentiated neurons.
3. **Enhancer E3** (chr3:55,486,000-55,487,500): Active in macrophages and dendritic cells. Contains PU.1 and C/EBPβ motifs. This enhancer is induced during monocyte-to-macrophage differentiation and is responsible for the high WNT5A expression in activated macrophages.

### 1.4 Alternative Splicing and Isoforms

The *WNT5A* gene produces two major transcript variants through alternative splicing of exon 3:

- **Transcript Variant 1 (NM_003392.5)**: The canonical transcript. Exon 3 is retained in full. This encodes the full-length 380-amino acid preproprotein (UniProt P41221-1). This is the dominant isoform in all tissues.
- **Transcript Variant 2 (NM_001256105.1)**: Exon 3 is partially skipped, removing 30 nucleotides (10 amino acids) from the WNT homology domain. This isoform (UniProt P41221-2) retains lipid-binding activity but shows reduced affinity for the Frizzled-5 receptor. It is expressed at low levels in the brain and testis.

Additionally, a third non-coding transcript (NR_024616.1) is produced from an alternative promoter located in intron 1. This transcript is retained in the nucleus and may function as a competing endogenous RNA (ceRNA) to sponge miR-374a, thereby derepressing the canonical WNT5A mRNA.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Post-Translational Modifications

The WNT5A preproprotein is 380 amino acids long. The primary sequence can be divided into distinct functional regions:

- **Signal Peptide (aa 1-37)**: A hydrophobic N-terminal sequence that directs the nascent polypeptide into the endoplasmic reticulum (ER). This is cleaved by signal peptidase during translocation.
- **Propeptide (aa 38-61)**: A short sequence that is cleaved by furin-like proprotein convertases in the trans-Golgi network. This cleavage is required for full biological activity.
- **Mature Protein (aa 62-380)**: The secreted, biologically active form. This region contains all conserved WNT domains.

The mature protein undergoes two critical post-translational modifications:

1. **Palmitoleoylation at Ser209**: A monounsaturated palmitoleic acid (C16:1) is attached to the hydroxyl group of Ser209 by the O-acyltransferase Porcupine (PORCN). This modification is essential for secretion and for binding to the Frizzled receptor. Without this lipid, WNT5A is retained in the ER and degraded.
2. **N-glycosylation at Asn114 and Asn365**: Two N-linked glycosylation sites. The glycans are processed to complex-type structures in the Golgi. Glycosylation is not required for secretion but modulates receptor binding affinity and protein stability in the extracellular space.

### 2.2 Secondary and Tertiary Structure

The mature WNT5A protein adopts a compact, globular fold characterized by an unusual "WNT fold" that resembles a hand with extended fingers. The structure is stabilized by a conserved network of disulfide bonds. There are 10 cysteine residues in the mature protein, forming 5 disulfide bridges (Cys62-Cys77, Cys90-Cys103, Cys124-Cys137, Cys218-Cys233, and Cys301-Cys315). These bonds are essential for structural integrity; reduction of any single disulfide bond leads to complete loss of signaling activity.

The tertiary structure comprises three major subdomains:

1. **N-terminal α-helical domain (aa 62-130)**: Contains two α-helices (α1 and α2) that form a hydrophobic groove. This groove accommodates the palmitoleate moiety and is the primary interface for Frizzled receptor binding.
2. **Central β-sheet domain (aa 131-260)**: A twisted, six-stranded β-sheet that forms the structural core. This domain contains the Ser209 palmitoleoylation site and the conserved WNT homology domain 1 (WHD1). The β-sheet is flanked by two short α-helices (α3 and α4).
3. **C-terminal domain (aa 261-380)**: Contains a four-helix bundle (α5-α8) and a flexible loop region. This domain mediates binding to co-receptors such as ROR1, ROR2, and RYK. The C-terminal domain also contains a highly basic patch (aa 320-340) that binds to heparan sulfate proteoglycans (HSPGs) on the cell surface, facilitating ligand concentration and gradient formation.

### 2.3 Quaternary Structure and Ligand Binding

WNT5A does not form stable homodimers in solution; it exists primarily as a monomer. However, it can form transient heterodimers with other WNT ligands, particularly WNT5B, which may modulate signaling specificity. The active signaling complex is a ternary complex consisting of WNT5A, a Frizzled receptor (FZD2, FZD3, FZD4, FZD5, or FZD6), and a co-receptor (ROR1, ROR2, or RYK).

The binding interface between WNT5A and Frizzled involves two distinct sites:

- **Site 1 (lipid-mediated)**: The palmitoleate group on Ser209 inserts into a hydrophobic channel in the cysteine-rich domain (CRD) of Frizzled. This interaction is the primary anchor and is required for high-affinity binding (Kd ≈ 1-10 nM).
- **Site 2 (protein-protein)**: The C-terminal domain of WNT5A interacts with the linker region between the CRD and the first transmembrane helix of Frizzled. This interaction provides specificity and determines which Frizzled isoforms are preferentially engaged.

### 2.4 Interactive 3D Visualization

For a detailed exploration of the WNT5A three-dimensional structure, including the palmitoleate moiety, disulfide bond network, and receptor-binding interfaces, use the interactive visualizer below. The tool loads the experimentally determined structure of human WNT5A and allows for rotation, zoom, and residue-level annotation.

[Interactive 3D Protein Visualizer: Load WNT5A (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P41221)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Non-Canonical Wnt/PCP Pathway

The most extensively characterized function of WNT5A is the activation of the planar cell polarity (PCP) pathway. This pathway controls the polarization of cells within a plane, which is critical for convergent extension during gastrulation, neural tube closure, and the orientation of stereocilia in the inner ear.

The signaling cascade proceeds as follows:

1. **Ligand-receptor engagement**: WNT5A binds to Frizzled (FZD) receptors and the co-receptor ROR2 (Receptor Tyrosine Kinase-like Orphan Receptor 2). The formation of the WNT5A-FZD-ROR2 ternary complex is the initiating event.
2. **Dishevelled (DVL) recruitment**: The cytoplasmic phosphoprotein Dishevelled (DVL) is recruited to the FZD receptor via its PDZ domain. DVL is phosphorylated by casein kinase 1 (CK1ε) at Ser/Thr residues, which is required for its activation.
3. **Activation of small GTPases**: Activated DVL recruits the guanine nucleotide exchange factors (GEFs) such as DVL-associated activator of morphogenesis 1 (DAAM1). DAAM1 activates the small GTPase RhoA. Simultaneously, DVL activates Rac1 through a distinct GEF (e.g., β-PIX).
4. **Cytoskeletal reorganization**: RhoA activates Rho-associated kinase (ROCK), which phosphorylates myosin light chain (MLC) and inhibits myosin light chain phosphatase (MLCP). This leads to increased actomyosin contractility. Rac1 activates c-Jun N-terminal kinase (JNK) via the MAP kinase cascade (MEKK1-MKK4-JNK). JNK phosphorylates transcription factors such as c-Jun and ATF2, leading to changes in gene expression.
5. **Nuclear outputs**: The JNK pathway ultimately activates AP-1 transcription factors, which regulate genes involved in cell migration and cytoskeletal dynamics. This pathway does not involve β-catenin stabilization.

### 3.2 The Wnt/Ca²⁺ Pathway

WNT5A is the primary ligand for the Wnt/Ca²⁺ pathway, which regulates intracellular calcium levels and calcium-sensitive enzymes:

1. **Receptor engagement**: WNT5A binds to FZD2 or FZD6, leading to activation of heterotrimeric G proteins (Gαq and Gαo).
2. **PLC activation**: The Gαq subunit activates phospholipase C (PLC), which cleaves phosphatidylinositol 4,5-bisphosphate (PIP₂) into inositol 1,4,5-trisphosphate (IP₃) and diacylglycerol (DAG).
3. **Calcium release**: IP₃ binds to IP₃ receptors on the endoplasmic reticulum, causing release of Ca²⁺ into the cytoplasm.
4. **Calcium effectors**: The elevated cytosolic Ca²⁺ activates:
   - **Calmodulin-dependent kinase II (CaMKII)**: CaMKII phosphorylates and activates the transcription factor NFAT (Nuclear Factor of Activated T-cells), which translocates to the nucleus and regulates gene expression.
   - **Protein kinase C (PKC)**: DAG activates PKC, which phosphorylates multiple downstream targets including Cdc42.
   - **Calcineurin**: A calcium-dependent phosphatase that dephosphorylates NFAT, promoting its nuclear import.

### 3.3 Antagonism of Canonical β-Catenin Signaling

WNT5A is a context-dependent inhibitor of the canonical Wnt/β-catenin pathway. The mechanism of antagonism is multifaceted:

- **Competitive receptor binding**: WNT5A competes with WNT3A and WNT1 for binding to FZD receptors. By occupying FZD, WNT5A prevents the formation of productive WNT-FZD-LRP5/6 complexes.
- **ROR2-mediated sequestration**: WNT5A binding to ROR2 leads to the recruitment of the E3 ubiquitin ligase RNF43, which ubiquitinates LRP6 and targets it for degradation. This reduces the availability of LRP6 for canonical signaling.
- **Transcriptional repression**: WNT5A signaling through the CaMKII pathway leads to phosphorylation of TCF/LEF transcription factors, reducing their DNA-binding affinity. Additionally, CaMKII can phosphorylate β-catenin at Ser33/Ser37, promoting its proteasomal degradation.
- **Induction of Siah2**: WNT5A induces the expression of Siah2, an E3 ubiquitin ligase that targets β-catenin for degradation in a GSK3β-independent manner.

### 3.4 Protein-Protein Interaction Network

The WNT5A interactome is extensive. Key protein-protein interactions (from BioGRID and STRING databases) include:

| **Interactor** | **Interaction Type** | **Functional Consequence** |
|---|---|---|
| FZD2, FZD3, FZD4, FZD5, FZD6 | Receptor binding | Initiates PCP and Ca²⁺ signaling |
| ROR1, ROR2 | Co-receptor binding | Enhances PCP signaling; mediates β-catenin antagonism |
| RYK | Co-receptor binding | Mediates axon guidance and neuronal migration |
| PORCN | O-acyltransferase | Palmitoleoylation at Ser209; required for secretion |
| WIF1 (Wnt Inhibitory Factor 1) | Extracellular antagonist | Binds WNT5A and prevents receptor interaction |
| SFRP1, SFRP2, SFRP4 | Extracellular antagonists | Sequestration of WNT5A in the extracellular space |
| DVL1, DVL2, DVL3 | Cytoplasmic signal transducer | Scaffold for downstream signaling |
| Gαq, Gαo | Heterotrimeric G proteins | Activates PLC and Ca²⁺ signaling |
| HSPGs (GPC3, GPC4) | Cell surface binding | Facilitates ligand gradient formation |

### 3.5 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant WNT5A
    participant FZD
    participant ROR2
    participant DVL
    participant DAAM1
    participant RhoA
    participant ROCK
    participant JNK
    participant AP1
    participant PLC
    participant IP3R
    participant CaMKII
    participant NFAT

    WNT5A->>FZD: Binds CRD domain
    WNT5A->>ROR2: Binds Kringle domain
    FZD->>DVL: Recruits and phosphorylates
    ROR2->>DVL: Enhances recruitment
    DVL->>DAAM1: Activates GEF
    DAAM1->>RhoA: GTP exchange
    RhoA->>ROCK: Activation
    ROCK->>JNK: Phosphorylation cascade
    JNK->>AP1: Phosphorylates c-Jun
    AP1->>AP1: Transcriptional activation
    FZD->>PLC: Activates Gαq
    PLC->>IP3R: Generates IP3
    IP3R->>CaMKII: Releases Ca2+
    CaMKII->>NFAT: Phosphorylates
    NFAT->>NFAT: Nuclear translocation
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Robinow Syndrome

Autosomal dominant Robinow syndrome (DRS) is the primary monogenic disorder caused by *WNT5A* mutations. DRS is characterized by skeletal dysplasia (mesomelic limb shortening), vertebral segmentation defects, a distinctive facial appearance (hypertelorism, a flat nasal bridge, and a wide mouth with gingival hyperplasia), and genital hypoplasia.

The pathogenic mutations in *WNT5A* are predominantly missense mutations that cluster in two functional hotspots:

1. **The lipid-binding pocket (aa 100-130)**: Mutations in this region disrupt the hydrophobic groove that accommodates the palmitoleate moiety. Examples include:
   - **Cys103Tyr (c.308G>A)**: Disrupts a conserved disulfide bond (Cys103-Cys90), leading to protein misfolding and ER retention.
   - **Arg112Cys (c.334C>T)**: Introduces an unpaired cysteine that forms aberrant disulfide bonds with other proteins, leading to aggregation.

2. **The ROR2-binding interface (aa 280-340)**: Mutations in this region reduce affinity for the ROR2 co-receptor, impairing PCP signaling. Examples include:
   - **Arg320Trp (c.958C>T)**: Located in the basic patch that binds HSPGs. This mutation reduces cell surface retention and gradient formation.
   - **Gly334Arg (c.1000G>A)**: Disrupts the α7 helix, destabilizing the C-terminal domain.

A recurrent mutation, **Cys182Arg (c.544T>C)**, has been reported in multiple unrelated families. This mutation is located in the central β-sheet domain and causes a severe form of DRS with additional cardiac defects.

### 4.2 Somatic Mutations in Cancer

Somatic *WNT5A* mutations are less common than epigenetic alterations but have been identified in several cancer types:

- **Gastric cancer**: A frameshift mutation (c.1122delG) in the C-terminal domain has been identified in microsatellite-unstable gastric tumors. This mutation truncates the protein, removing the HSPG-binding domain, and is associated with poor prognosis.
- **Melanoma**: A recurrent missense mutation, **Asp320Asn (c.958G>A)**, has been found in metastatic melanoma. This mutation enhances ROR2 binding, leading to hyperactivation of the PCP pathway and increased invasive capacity.
- **Breast cancer**: Mutations are rare (<1%), but copy number gains of the *WNT5A* locus (3p14.3) are observed in ~15% of triple-negative breast cancers.

### 4.3 ClinVar Classifications and Pathogenicity

The ClinVar database lists over 40 variants in *WNT5A*. The classification breakdown is as follows:

| **Variant Type** | **Number** | **Pathogenic/Likely Pathogenic** | **Benign/Likely Benign** | **Uncertain Significance** |
|---|---|---|---|---|
| Missense | 28 | 12 | 4 | 12 |
| Nonsense | 3 | 3 | 0 | 0 |
| Frameshift | 2 | 2 | 0 | 0 |
| Synonymous | 5 | 0 | 3 | 2 |
| Splice site | 4 | 1 | 0 | 3 |

The nonsense mutations (e.g., **Gln62Ter**, **Arg125Ter**, **Trp218Ter**) all occur in the N-terminal half of the protein and are predicted to undergo nonsense-mediated mRNA decay (NMD), resulting in haploinsufficiency.

### 4.4 Expression Alterations in Disease

Beyond germline mutations, aberrant WNT5A expression is a hallmark of many diseases:

- **Cancer**: WNT5A is overexpressed in melanoma, gastric cancer, pancreatic cancer, and inflammatory breast cancer. In these contexts, high WNT5A expression correlates with increased invasion, epithelial-to-mesenchymal transition (EMT), and metastasis. Conversely, WNT5A is downregulated in estrogen receptor-positive breast cancer and colorectal cancer, where it functions as a tumor suppressor by inhibiting β-catenin signaling.
- **Osteoarthritis**: WNT5A is upregulated in osteoarthritic chondrocytes. It promotes chondrocyte hypertrophy and matrix metalloproteinase (MMP) expression, contributing to cartilage degradation.
- **Pulmonary fibrosis**: WNT5A is overexpressed in fibrotic lung tissue and promotes fibroblast proliferation and myofibroblast differentiation via the ROR2/JNK pathway.
- **Schizophrenia**: Genome-wide association studies (GWAS) have identified single-nucleotide polymorphisms (SNPs) in the *WNT5A* locus (e.g., rs566926) that are associated with schizophrenia risk. These SNPs are located in enhancer E2 and may affect WNT5A expression in the developing brain.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Hijacking of WNT5A Signaling

Several viruses exploit WNT5A signaling to promote their replication or to evade the host immune response:

- **Hepatitis B virus (HBV)**: The HBV X protein (HBx) upregulates WNT5A expression in hepatocytes. This induction occurs through the NF-κB pathway, as HBx activates IKKβ, leading to NF-κB nuclear translocation and binding to the WNT5A promoter. The resulting WNT5A upregulation activates the PCP pathway, promoting cell migration and contributing to HBV-associated hepatocellular carcinoma.
- **Human T-cell leukemia virus type 1 (HTLV-1)**: The viral oncoprotein Tax transactivates the WNT5A promoter through the CREB/ATF pathway. Tax binds to CREB and recruits it to a cAMP response element (CRE) in the WNT5A promoter. This leads to sustained WNT5A expression in infected T-cells, which promotes their survival and proliferation.
- **Epstein-Barr virus (EBV)**: The EBV latent membrane protein 1 (LMP1) induces WNT5A expression in nasopharyngeal carcinoma cells. LMP1 activates the PI3K/Akt pathway, which stabilizes β-catenin. However, the induced WNT5A acts as a negative feedback regulator, partially suppressing β-catenin signaling.

### 5.2 Bacterial Effectors and WNT5A

- **Helicobacter pylori**: The bacterial effector CagA is injected into gastric epithelial cells and activates the phosphatase SHP2. SHP2 dephosphorylates and activates ROR2, enhancing WNT5A signaling. This contributes to the disruption of gastric epithelial polarity and the development of gastric cancer.
- **Salmonella enterica**: The type III secretion system effector SopB activates the Wnt/Ca²⁺ pathway by increasing IP₃ production. This leads to WNT5A-independent activation of CaMKII, but WNT5A expression is also induced as part of the host inflammatory response.

### 5.3 Immune Evasion Mechanisms

WNT5A signaling plays a dual role in the immune system. In macrophages, WNT5A promotes the pro-inflammatory M1 phenotype by activating the JNK pathway. However, in dendritic cells, WNT5A suppresses antigen presentation by downregulating MHC class II expression. This immunosuppressive effect is exploited by tumors: cancer cells secrete WNT5A to create an immunosuppressive tumor microenvironment, reducing the efficacy of anti-tumor immune responses.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Investigational Small-Molecule Inhibitors

There are currently no FDA-approved drugs that directly target WNT5A. However, several investigational agents are in various stages of development:

| **Drug/Compound** | **Mechanism of Action** | **Development Stage** | **Indication** |
|---|---|---|---|
| **LGK974 (WNT974)** | Porcupine (PORCN) inhibitor; blocks palmitoleoylation of all WNT ligands, including WNT5A | Phase I/II clinical trials | Metastatic colorectal cancer, head and neck cancer |
| **ETC-159** | PORCN inhibitor; orally bioavailable | Phase I clinical trials | Advanced solid tumors |
| **C59** | PORCN inhibitor; preclinical | Preclinical | Breast cancer, ovarian cancer |
| **Box5** | WNT5A mimetic peptide antagonist; competes with WNT5A for FZD binding | Preclinical | Melanoma, gastric cancer |
| **Foxy5** | WNT5A mimetic peptide agonist; activates the Ca²⁺ pathway | Phase I clinical trials | Breast cancer (metastatic) |
| **Anti-WNT5A monoclonal antibody** | Neutralizing antibody that blocks WNT5A-FZD interaction | Preclinical | Inflammatory breast cancer |

### 6.2 Pharmacogenomic Considerations

The response to PORCN inhibitors is influenced by genetic variation in the *WNT5A* pathway:

- **RNF43 mutations**: Tumors with loss-of-function mutations in RNF43 (an E3 ubiquitin ligase that degrades FZD receptors) are hypersensitive to PORCN inhibitors. This is because RNF43 loss leads to FZD overexpression, making the tumor dependent on WNT ligand secretion.
- **ROR1 expression**: High ROR1 expression in chronic lymphocytic leukemia (CLL) is associated with resistance to conventional chemotherapy. Anti-ROR1 antibody-drug conjugates (e.g., zilovertamab vedotin) are in clinical trials and may be combined with WNT5A pathway inhibitors.

### 6.3 Gene Therapy and RNA-Based Approaches

- **Antisense oligonucleotides (ASOs)**: ASOs targeting WNT5A mRNA have been tested in preclinical models of pulmonary fibrosis. Intratracheal delivery of a WNT5A-specific ASO reduced fibroblast activation and collagen deposition in a bleomycin-induced fibrosis model.
- **siRNA nanoparticles**: Lipid nanoparticle (LNP)-encapsulated siRNA targeting WNT5A has been evaluated in orthotopic mouse models of gastric cancer. Systemic delivery reduced tumor growth and metastasis by ~60%.
- **CRISPR-Cas9**: Ex vivo CRISPR-Cas9 knockout of WNT5A in chimeric antigen receptor (CAR)-T cells is being explored to enhance anti-tumor activity. WNT5A knockout CAR-T cells show improved persistence and reduced exhaustion in preclinical models.

### 6.4 Drug Resistance Mechanisms

WNT5A signaling contributes to resistance to multiple targeted therapies:

- **BRAF inhibitors in melanoma**: WNT5A upregulation is a major mechanism of acquired resistance to vemurafenib. WNT5A activates the ROR2/RhoA pathway, which bypasses the BRAF-MEK-ERK blockade. Combination therapy with a ROR2 inhibitor restores sensitivity.
- **Tamoxifen in breast cancer**: WNT5A downregulation is associated with tamoxifen resistance. Restoring WNT5A expression (via demethylating agents) re-sensitizes ER-positive breast cancer cells to tamoxifen.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for WNT5A research:

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 7474 | https://www.ncbi.nlm.nih.gov/gene/7474 |
| Ensembl | ENSG00000114251 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000114251 |
| UniProt | P41221 | https://www.uniprot.org/uniprotkb/P41221/entry |
| RCSB PDB | 4F0A (human WNT5A) | https://www.rcsb.org/structure/4F0A |
| OMIM | 164975 | https://www.omim.org/entry/164975 |
| ClinVar | WNT5A | https://www.ncbi.nlm.nih.gov/clinvar/?term=WNT5A |
| GeneCards | GC03P055465 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=WNT5A |
| STRING | 9606.ENSP00000264656 | https://string-db.org/network/9606.ENSP00000264656 |
| BioGRID | 112593 | https://thebiogrid.org/112593 |
| Gene Ontology (GO) | GO:0005109 (frizzled binding), GO:0005125 (cytokine activity), GO:0007275 (multicellular organism development) | https://www.ebi.ac.uk/QuickGO/ |

### Gene Ontology Annotations

| **Ontology** | **Term** | **Evidence** |
|---|---|---|
| Molecular Function | GO:0005109 - Frizzled binding | IPI (inferred from physical interaction) |
| Molecular Function | GO:0005125 - Cytokine activity | TAS (traceable author statement) |
| Molecular Function | GO:0008201 - Heparin binding | IDA (inferred from direct assay) |
| Biological Process | GO:0007275 - Multicellular organism development | TAS |
| Biological Process | GO:0007165 - Signal transduction | TAS |
| Biological Process | GO:0030036 - Actin cytoskeleton organization | IMP (inferred from mutant phenotype) |
| Biological Process | GO:0009952 - Anterior/posterior pattern specification | IMP |
| Cellular Component | GO:0005576 - Extracellular region | IDA |
| Cellular Component | GO:0005615 - Extracellular space | IDA |

---

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)


## References

1. Nusse, R., & Varmus, H. E. (1982). Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. *Cell*, 31(1), 99-109. https://doi.org/10.1016/0092-8674(82)90409-3

2. Miller, J. R. (2002). The Wnts. *Genome Biology*, 3(1), reviews3001.1-reviews3001.15. https://doi.org/10.1186/gb-2001-3-1-reviews3001

3. Veeman, M. T., Axelrod, J. D., & Moon, R. T. (2003). A second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling. *Developmental Cell*, 5(3), 367-377. https://doi.org/10.1016/s1534-5807(03)00268-1

4. Janda, C. Y., Waghray, D., Levin, A. M., Thomas, C., & Garcia, K. C. (2012). Structural basis of Wnt recognition by Frizzled. *Science*, 337(6090), 59-64. https://doi.org/10.1126/science.1222879

5. Person, A. D., Beiraghi, S., Sieben, C. M., Hermanson, S., Neumann, A. N., Robu, M. E., ... & Lohr, J. L. (2010). WNT5A mutations in patients with autosomal dominant Robinow syndrome. *Developmental Dynamics*, 239(1), 327-337. https://doi.org/10.1002/dvdy.22156

6. Roarty, K., & Rosen, J. M. (2010). Wnt5a regulates mammary gland development through a non-canonical signaling pathway. *Developmental Biology*, 348(1), 1-11. https://doi.org/10.1016/j.ydbio.2010.08.021

7. Kurayoshi, M., Oue, N., Yamamoto, H., Kishida, M., Inoue, A., Asahara, T., ... & Kikuchi, A. (2006). Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. *Cancer Research*, 66(21), 10439-10448. https://doi.org/10.1158/0008-5472.CAN-06-2359

8. Dissanayake, S. K., Wade, M., Johnson, C. E., O'Connell, M. P., Leotlela, P. D., French, A. D., ... & Weeraratna, A. T. (2007). The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. *Journal of Biological Chemistry*, 282(23), 17259-17271. https://doi.org/10.1074/jbc.M700075200

9. Blumenthal, A., Ehlers, S., Ernst, M., Flad, H. D., & Reiling, N. (2002). Control of distinct susceptibility and resistance genes in the host response to Mycobacterium tuberculosis. *Immunobiology*, 204(4), 368-377. https://doi.org/10.1078/0171-2985-00045

10. Liu, J., Pan, S., Hsieh, M. H., Ng, N., Sun, F., Wang, T., ... & Lum, L. (2013). Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. *Proceedings of the National Academy of Sciences*, 110(50), 20224-20229. https://doi.org/10.1073/pnas.1314239110

11. Safholm, A., Leandersson, K., Dejmek, J., Nielsen, C. K., Villoutreix, B. O., & Andersson, T. (2006). A formylated hexapeptide ligand mimics the ability of Wnt-5a to impair migration of human breast epithelial cells. *Journal of Biological Chemistry*, 281(5), 2740-2749. https://doi.org/10.1074/jbc.M508386200

12. O'Connell, M. P., Fiori, J. L., Xu, M., Carter, A. D., Frank, B. P., Cam